4th Quarter - Termination Amendment

PKD FOUNDATION for PKD FOUNDATION

Firm
Client
Income
—
Expenses
$20,000
Expense method
A: Lobbying Disclosure Act definitions
Terminated
Dec 22, 2011

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
4th Quarter - Report Jan 20, 2011 $20,000 Replaced
4th Quarter - Termination Amendment (this page) Dec 17, 2012 $20,000 Yes

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

Report language to the FY 2011 Labor-Health and Human Services-Education Appropriations Act supporting PKD research at the National Institute of Diabetes, Digestive and Kidney Disease (NIDDK); support for increasing overall funding for the National Institutes of Health (NIH)

LobbyistCovered position, as disclosed
KIMBERLY CANTOR —
DAN E LARSON —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Health Issues HCR

Seeking co-sponsorship for and passage of the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act (HR 1458/S 565)

LobbyistCovered position, as disclosed
KIMBERLY CANTOR —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 1458 (111th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.